![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring
A combination featuring Exelixis’ zanzalintinib has beaten Bayer’s Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.
A combination featuring Exelixis’ zanzalintinib has beaten Bayer’s Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.
